Cancer

Combinatorial therapy for prostate cancer:  A therapeutic mix encompassing  Simvastatin and Navitoclax/ABT-263 (SAN) inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via up regualtion of its target gene, 20/February/2019, 12.09 am
Combinatorial therapy for prostate cancer:  A therapeutic mix encompassing  Simvastatin and Navitoclax/ABT-263 (SAN) inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via up regualtion of its target gene, 20/February/2019, 12.09 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from CIC bioGUNE (Center for Cooperative Research in Biosciences), Bizkaia Technology Park, 801 Building, 48160 Derio, Spain shows that “mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.” This…

read more

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  Fenofibrate and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 19/February/2019, `3.13 pm
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  Fenofibrate and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 19/February/2019, `3.13 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that:  Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors…

read more

Combinatorial therapy for glioblastoma: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) [SAN] inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down-regulation of its target gene, 18/February/2019, 1.07 pm
Combinatorial therapy for glioblastoma: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) [SAN] inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down-regulation of its target gene, 18/February/2019, 1.07 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:  A study from the Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Ohio, USA shows that “Transcription elongation factors represent in vivo cancer…

read more

Combinatorial therapy for drug-resistant cancers: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) (SAN) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via upregulation of its target gene, 18/February/2019, 12.49 pm
Combinatorial therapy for drug-resistant cancers: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) (SAN) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via upregulation of its target gene, 18/February/2019, 12.49 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Broad Institute, Cambridge, Massachusetts, USA, Howard Hughes Medical Institute, Chevy Chase, Maryland and Department of Chemistry and Chemical Biology, Harvard University, Oxford St., Cambridge,…

read more

Combinatorial therapy for Notch1-overexpressing Human cancers: A therapeutic mix encompassing  Metformin and Navitoclax/ABT-263 (MAN) inhibits the expression of Notch1, and adhesion molecule VCAM1, suppresses neutrophil infiltration and tumor cell adhesion to endothelium and prevents Notch1-driven metastasis via upregulation of its target gene, 15/February/2019, 7.26 am
Combinatorial therapy for Notch1-overexpressing Human cancers: A therapeutic mix encompassing  Metformin and Navitoclax/ABT-263 (MAN) inhibits the expression of Notch1, and adhesion molecule VCAM1, suppresses neutrophil infiltration and tumor cell adhesion to endothelium and prevents Notch1-driven metastasis via upregulation of its target gene, 15/February/2019, 7.26 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Vascular Signaling and Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Vascular Biology, CBTM, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim,…

read more

Combinatorial therapy for prostate cancer bone metastasis:  A pharmaceutical mixture encompassing Metformin and Navitoclax (MAN) inhibits the expression of Monoamine oxidase A (MAOA), inhibits Shh-IL6-RANKL signaling network, suppresses tumor-stromal interactions, reduces prostate cancer metastasis and prolongs survival via upregulation of its target gene, 15/February/2019, 6.21 am
Combinatorial therapy for prostate cancer bone metastasis:  A pharmaceutical mixture encompassing Metformin and Navitoclax (MAN) inhibits the expression of Monoamine oxidase A (MAOA), inhibits Shh-IL6-RANKL signaling network, suppresses tumor-stromal interactions, reduces prostate cancer metastasis and prolongs survival via upregulation of its target gene, 15/February/2019, 6.21 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Uro-Oncology Research Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA shows that “MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes…

read more
Start Typing